Tags

Type your tag names separated by a space and hit enter

Cell blocks allow reliable evaluation of expression of basal (CK5/6) and luminal (CK8/18) cytokeratins and smooth muscle actin (SMA) in breast carcinoma.
Cytopathology. 2010 Aug; 21(4):259-66.C

Abstract

OBJECTIVE

Gene expression studies have revealed several molecular subtypes of breast carcinoma with distinct clinical and biological behaviours. DNA microarray studies correlated with immunohistochemical profiling of breast carcinomas using cytokeratin (CK) markers, Her2/neu, oestrogen receptor (ER), and basal myoepithelial cell markers have identified five breast tumour subtypes: (i) luminal A (ER+; Her2/neu-), (ii) luminal B (ER+; Her2/neu+), (iii) Her2 overexpression (ER-; Her2/neu+), (iv) basal-like (ER-; Her2/neu-, CK5/6 and 14+), and (v) negative for all markers. Luminal carcinomas express cytokeratins in a luminal pattern (CK8/18), and the basal-like type expresses CK5/6 and CK14 or basal epithelial cell markers. CK5/6, CK8/18, and smooth muscle actin (SMA) expression were assessed in cell blocks and compared with expression in surgical specimens.

METHODS

Sixty-two cases of breast carcinoma diagnosed by fine needle aspiration cytology with cell blocks and available surgical specimens were included. Cell blocks containing at least 10 high-power fields each with at least 10 tumour cells and surgical specimens were immunostained for CK5/6, CK8/18 and SMA.

RESULTS

Percentage sensitivity, specificity, positive predictive value, negative predictive value and accuracy were, respectively, 77, 100, 100, 92 and 94 for CK5/6; 98, 66, 96, 80 and 95 for CK8/18; and 92, 96, 85, 98 and 95 for SMA.

CONCLUSION

The identification of CK5/6, CK8/18 and SMA by immunohistochemistry in cell blocks can be a reliable method that yields results close to those obtained in surgical specimens, and can contribute to the classification of breast carcinomas with luminal and basal expression patterns, providing helpful information in the choice of treatment and in the evaluation of prognostic and predictive factors.

Authors+Show Affiliations

Mastology Post-Graduate Program, Medical School of Botucatu, São Paulo State University (UNESP-Botucatu), Botucatu, SP, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19843143

Citation

Delgallo, W D., et al. "Cell Blocks Allow Reliable Evaluation of Expression of Basal (CK5/6) and Luminal (CK8/18) Cytokeratins and Smooth Muscle Actin (SMA) in Breast Carcinoma." Cytopathology : Official Journal of the British Society for Clinical Cytology, vol. 21, no. 4, 2010, pp. 259-66.
Delgallo WD, Rodrigues JR, Bueno SP, et al. Cell blocks allow reliable evaluation of expression of basal (CK5/6) and luminal (CK8/18) cytokeratins and smooth muscle actin (SMA) in breast carcinoma. Cytopathology. 2010;21(4):259-66.
Delgallo, W. D., Rodrigues, J. R., Bueno, S. P., Viero, R. M., & Soares, C. T. (2010). Cell blocks allow reliable evaluation of expression of basal (CK5/6) and luminal (CK8/18) cytokeratins and smooth muscle actin (SMA) in breast carcinoma. Cytopathology : Official Journal of the British Society for Clinical Cytology, 21(4), 259-66. https://doi.org/10.1111/j.1365-2303.2009.00713.x
Delgallo WD, et al. Cell Blocks Allow Reliable Evaluation of Expression of Basal (CK5/6) and Luminal (CK8/18) Cytokeratins and Smooth Muscle Actin (SMA) in Breast Carcinoma. Cytopathology. 2010;21(4):259-66. PubMed PMID: 19843143.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cell blocks allow reliable evaluation of expression of basal (CK5/6) and luminal (CK8/18) cytokeratins and smooth muscle actin (SMA) in breast carcinoma. AU - Delgallo,W D, AU - Rodrigues,J R P, AU - Bueno,S P, AU - Viero,R M, AU - Soares,C T, Y1 - 2009/10/15/ PY - 2009/10/22/entrez PY - 2009/10/22/pubmed PY - 2010/10/20/medline SP - 259 EP - 66 JF - Cytopathology : official journal of the British Society for Clinical Cytology JO - Cytopathology VL - 21 IS - 4 N2 - OBJECTIVE: Gene expression studies have revealed several molecular subtypes of breast carcinoma with distinct clinical and biological behaviours. DNA microarray studies correlated with immunohistochemical profiling of breast carcinomas using cytokeratin (CK) markers, Her2/neu, oestrogen receptor (ER), and basal myoepithelial cell markers have identified five breast tumour subtypes: (i) luminal A (ER+; Her2/neu-), (ii) luminal B (ER+; Her2/neu+), (iii) Her2 overexpression (ER-; Her2/neu+), (iv) basal-like (ER-; Her2/neu-, CK5/6 and 14+), and (v) negative for all markers. Luminal carcinomas express cytokeratins in a luminal pattern (CK8/18), and the basal-like type expresses CK5/6 and CK14 or basal epithelial cell markers. CK5/6, CK8/18, and smooth muscle actin (SMA) expression were assessed in cell blocks and compared with expression in surgical specimens. METHODS: Sixty-two cases of breast carcinoma diagnosed by fine needle aspiration cytology with cell blocks and available surgical specimens were included. Cell blocks containing at least 10 high-power fields each with at least 10 tumour cells and surgical specimens were immunostained for CK5/6, CK8/18 and SMA. RESULTS: Percentage sensitivity, specificity, positive predictive value, negative predictive value and accuracy were, respectively, 77, 100, 100, 92 and 94 for CK5/6; 98, 66, 96, 80 and 95 for CK8/18; and 92, 96, 85, 98 and 95 for SMA. CONCLUSION: The identification of CK5/6, CK8/18 and SMA by immunohistochemistry in cell blocks can be a reliable method that yields results close to those obtained in surgical specimens, and can contribute to the classification of breast carcinomas with luminal and basal expression patterns, providing helpful information in the choice of treatment and in the evaluation of prognostic and predictive factors. SN - 1365-2303 UR - https://www.unboundmedicine.com/medline/citation/19843143/Cell_blocks_allow_reliable_evaluation_of_expression_of_basal__CK5/6__and_luminal__CK8/18__cytokeratins_and_smooth_muscle_actin__SMA__in_breast_carcinoma_ L2 - https://doi.org/10.1111/j.1365-2303.2009.00713.x DB - PRIME DP - Unbound Medicine ER -